There is new hope for prostate cancer patients as Aga Khan University Hospital pioneers advanced nuclear medicine therapy in Kenya. Aga Khan Chief Executive Officer, Rashid Khalani announced the introduction of Lutetium-177 PSMA therapy at their facility, highlighting a significant advancement in prostate cancer treatment in Kenya. This initiative aims to reduce the necessity for patients to seek specialised medical care abroad, reducing the financial and emotional burden of international travel. “As a hospital, we are committed to bringing the most advanced treatments to Kenya so that we can significantly improve patient outcomes,” he emphasised.